New trial registered for Songling Xuemaikang Capsules in hypertension with insomnia
A study testing whether the traditional Chinese medicine capsule can lower blood pressure in hypertensive patients with insomnia was listed on ClinicalTrials.gov.
A single registry entry this week covers a new study of Songling Xuemaikang Capsules.
- "Songling Xuemaikang Capsules in Hypertension and Insomnia Evaluation" (SHINE, NCT07709442) is a randomized, double-blind, placebo-controlled multicenter study that is not yet recruiting, with an estimated start date of 2026-06-30. The trial aims to evaluate the effect of Songling Xuemaikang Capsules on reducing 24-hour mean blood pressure in patients with hypertension accompanied by insomnia.1 The study lists Jing Liu as lead sponsor and Chengdu Kanghong Pharmaceutical Group Co., Ltd. as a collaborator.1 The product itself is described as an exclusive product of Chengdu Kanghong Pharmaceutical Co., Ltd., approved for marketing on February 12, 1996.1 Its formula is described as Pini Massonianae Folium (fresh pine needle), Puerariae Lobatae Radix (kudzu root), and Concha Margaritifera Usta (nacre powder).1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.